Jaypirca
Generic name: Pirtobrutinib
Dosage form: Oral tablets
Drug class:
BTK inhibitors
Usage of Jaypirca
Jaypirca (pirtobrutinib) is an oral kinase inhibitor that is approved under the accelerated approval classification to treat adults with:
How does Jaypirca work?
Jaypirca works by blocking BTK which is a signaling protein found across numerous B-cell leukemia and lymphomas including MCL, CLL, and SLL, that when stimulated, activates pathways responsible for B-cell proliferation, activity, and growth. This blocks the activity that leads to the growth of the B-cells and causes cell death of the malignant B-cells. Jaypirca belongs to the class of drugs called Bruton's tyrosine kinase (BTK) inhibitors and is highly selective for BTK (300 times more selective than most other kinases).
Jaypirca was the first non-covalent (reversible) BTK inhibitor to be approved. It can reestablish BTK inhibition in patients previously treated with a covalent BTK inhibitor (Ibrutinib, acalabrutinib, or Zanubrutinib) and extend the benefit of targeting the BTK pathway.
Jaypirca was first FDA-approved on January 27, 2023.
Jaypirca side effects
Jaypirca can cause serious side effects, including:
The most common Jaypirca side effects affecting 20% or more people include:
Other side effects may include:
These are not all the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Before taking Jaypirca
Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:
Pregnancy and breastfeeding
Your healthcare provider will do a pregnancy test before starting treatment in females who can become pregnant. You should use effective birth control (contraception) during treatment and for 1 week after your last dose. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment.
It is not known if Jaypirca passes into your breast milk. Do not breastfeed during treatment, and for 1 week after your last dose.
Relate drugs
How to use Jaypirca
Take Jaypirca tablets exactly as your healthcare provider tells you.
The recommended doSage of MCL, CLL/SLL is 200 mg orally once daily.
Warnings
Serious and deadly infections caused by bacteria, viruses, or fungi have occurred with Jaypirca, 24% were Grade 3 or higher; opportunistic infections such as those caused by Pneumocystis jirovecci pneumonia also occurred. Consider prophylaxis, such as vaccinations and antibiotics in those at increased risk.
Serious and fatal bleeding events (hemorrhage) have also occurred with Jaypirca. Monitor for any signs of bleeding and manage appropriately.
Cytopenias, such as low neutrophils, platelets, or red blood cells can occur. Your healthcare provider will monitor your blood counts regularly throughout treatment.
Cardiac arrhythmia including atrial fibrillation and atrial flutter and second primary cancers, including skin cancers, have also occurred. Use sun protection when outside.
Can cause fetal harm. Females of reproductive potential should use effective contraception.
It is not known if this medicine is safe and effective in children.
What other drugs will affect Jaypirca
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Jaypirca with certain other medicines may affect how Jaypirca or the other medicines work and can cause side effects.
Jaypirca interacts with other drugs that are metabolized in a certain way. Tell your doctor if you are taking medicines that contain any of the following drugs:
Jaypirca may also interact with grapefruit juice, though the effect varies widely among brands of grapefruit juice.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions